BioNTech Inkomsten in het verleden

Verleden criteriumcontroles 0/6

BioNTech is de winst gegroeid met een gemiddeld jaarlijks percentage van 11.5%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.3%. De inkomsten zijn gegroeid met een gemiddelde van 17.2% per jaar.

Belangrijke informatie

11.5%

Groei van de winst

11.6%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	17.2%
Rendement op eigen vermogen	-2.4%
Nettomarge	-15.4%
Volgende winstupdate	05 May 2025

Recente prestatie-updates uit het verleden

Recent updates

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

Nov 06

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Nov 06

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

Jun 16

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29

Opbrengsten en kosten

Hoe BioNTech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:BNTX Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	3,040	-467	609	2,220
30 Jun 24	2,691	-504	612	2,168
31 Mar 24	2,730	113	566	1,957
31 Dec 23	3,819	930	558	1,783
30 Sep 23	6,618	2,751	550	1,715
30 Jun 23	9,184	4,375	550	1,559
31 Mar 23	12,213	6,238	560	1,585
31 Dec 22	17,311	9,434	541	1,537
30 Sep 22	18,565	10,322	556	1,299
30 Jun 22	21,191	11,748	480	1,217
31 Mar 22	23,303	12,863	394	1,019
31 Dec 21	18,977	10,293	327	949
30 Sep 21	13,790	7,493	229	935
30 Jun 21	7,770	4,072	178	902
31 Mar 21	2,503	1,197	139	796
31 Dec 20	482	15	109	645
30 Sep 20	165	-410	79	453
30 Jun 20	126	-230	63	275
31 Mar 20	110	-192	57	232
31 Dec 19	109	-179	49	227
30 Sep 19	144	-122	53	208
30 Jun 19	136	-116	48	191
31 Mar 19	132	-77	38	168
31 Dec 18	128	-48	32	141
31 Dec 17	62	-86	34	82

Kwaliteitswinsten: BNTX is momenteel verliesgevend.

Groeiende winstmarge: BNTX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: BNTX is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 11.5% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van BNTX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: BNTX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: BNTX heeft een negatief Return on Equity ( -2.44% ), omdat het momenteel verliesgevend is.

BioNTech Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

Consensus EPS estimates fall by 15%

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

New major risk - Revenue and earnings growth

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech's Oncology Gamble: High Stakes, Big Potential

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Consensus EPS estimates fall by 24%

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to €1.74 loss

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioNTech Earnings Preview: I Will Stay On The Sidelines

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Consensus EPS estimates fall by 11%

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Consensus EPS estimates have been downgraded.

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Now 21% undervalued after recent price drop

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 13%

Independent Supervisory Board Chairman notifies of intention to sell stock

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%